Grabengasse 1
Heidelberg, 69117
Germany
Hormone receptor, neoadjuvant, therapy Response, prognosis, breast cancer, endocrine therapy, triple-negative
Trastuzumab; Pertuzumab; De-escalation; Pathologic complete response; FDG-PET/CT; HER2-positive; Early breast cancer